all microvasive endoscopy products
מדיסון פארמה בע"מ - רופא - אנדוסקופים ומיכשור לאורולוגיה
all e.p.t. tech.products(a boston sci.di
boston scientific isr - רופא
all huntleigh products
trunof - כלל האוכלוסיה - מיטות מזרונים ומערכות העברה לחולים
all cordis-europa n.v. products
j-c healthcare ltd. - רופא - רדיולוגיה : צנתרים, שרווליות, בלונים, seriw ועזרים אחרים
לוטאטרה 370 mbqml תמיסה לעירוי
marshall isotope ltd, israel - lutetium (177lu) oxodotreotide - תמיסה לאינפוזיה - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide
לוטאטרה 370 mbqml תמיסה לעירוי
marshall isotope ltd, israel - lutetium (177lu) oxodotreotide - תמיסה לאינפוזיה - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide
אלימטה 500 מג
eli lilly israel ltd, israel - pemetrexed - אבקה להכנת תמיסה לאינפוזיה - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
אלימטה 500 מג
eli lilly israel ltd, israel - pemetrexed - אבקה להכנת תמיסה לאינפוזיה - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.